Imatinib mesylate is a targeted therapy. Imatinib mesylate is classified as a signal transduction inhibitor - protein-tyrosine kinase inhibitor.
Used for treatment of newly diagnosed adult and pediatric patients with philadelphia chromosome positive chronic myeloid leukemia (ph+ cml) in chronic phase.
Ph+ cml in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy.
Adult patients with relapsed or refractory philadelphia chromosome + acute lymphoblastic leukemia (ph+ all).
Adult patients with myelodysplasticmyeloproliferative diseases (mdsmpd) associated with pdgfr gene rearrangements.
Gastrointestinal stromal tumors that are c-kit positive.
Imatinib mesylate is a pill, taken by mouth, once or twice daily.
Imatinib mesylate should be taken with a large glass of water, after a meal.

Imatinib mesylate is a targeted therapy. Imatinib mesylate is classified as a signal transduction inhibitor - protein-tyrosine kinase inhibitor.
Used for treatment of newly diagnosed adult and pediatric patients with philadelphia chromosome positive chronic myeloid leukemia (ph+ cml) in chronic phase.
Ph+ cml in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy.
Adult patients with relapsed or refractory philadelphia chromosome + acute lymphoblastic leukemia (ph+ all).
Adult patients with myelodysplasticmyeloproliferative diseases (mdsmpd) associated with pdgfr gene rearrangements.
Gastrointestinal stromal tumors that are c-kit positive.
Imatinib mesylate is a pill, taken by mouth, once or twice daily.
Imatinib mesylate should be taken with a large glass of water, after a meal.